RLMD · Relmada Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $8.09M | - | $4.04M | $2.82M | $11.95M | - | $11.15M | $10.72M | $13.31M | - |
| SG&A | $11.37M | - | $6.29M | $7.40M | $6.27M | - | $11.86M | $8.10M | $9.68M | - |
| Total Operating Expenses | $19.46M | - | $10.33M | $10.22M | $18.22M | - | $23.01M | $18.82M | $22.99M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($19.46M) | - | ($10.33M) | ($10.22M) | ($18.22M) | - | ($23.01M) | ($18.82M) | ($22.99M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($19.05M) | - | ($10.09M) | ($9.87M) | ($17.56M) | - | ($21.73M) | ($17.77M) | ($21.83M) | - |
| EPS - Basic | ($0.22) | - | ($0.30) | ($0.30) | ($0.58) | - | ($0.72) | ($0.59) | ($0.72) | - |
| EPS - Diluted | ($0.22) | - | ($0.30) | ($0.30) | ($0.58) | - | ($0.72) | ($0.59) | ($0.72) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.78M | $3.50M | $1.38M | $1.35M | $1.15M | $3.86M | $1.48M | $2.09M | $1.34M | $4.09M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $5.73M | $1.57M | $1.45M | $1.36M | $1.27M | $4.13M | $2.35M | $4.17M | $5.19M | $3.51M |
| Current Assets | $235.34M | $93.98M | $14.85M | $21.09M | $27.66M | $45.80M | $55.70M | $70.97M | $84.37M | $97.51M |
| Total Assets | $235.36M | $94.00M | $14.88M | $21.12M | $27.68M | $45.82M | $55.72M | $71.03M | $84.41M | $97.55M |
| Current Liabilities | $12.89M | $6.43M | $5.19M | $5.13M | $5.23M | $10.29M | $8.09M | $9.54M | $12.36M | $12.19M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $16.63M | $7.49M | $5.41M | $5.17M | $5.24M | $10.30M | $8.10M | - | $12.36M | $12.19M |
| Stockholders' Equity | $218.73M | $86.51M | $9.47M | $15.95M | $22.44M | $35.52M | $47.63M | $61.49M | $72.05M | $85.36M |
| Retained Earnings | ($717.32M) | ($698.27M) | ($678.40M) | ($668.31M) | ($658.44M) | ($640.88M) | ($622.22M) | ($600.50M) | ($582.73M) | ($560.90M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($15.07M) | - | - | - | ($18.07M) | - | - | - | ($13.04M) | - |
| Investing Cash Flow | ($135.23M) | - | - | - | $15.36M | - | - | - | $10.06M | - |
| Financing Cash Flow | $156.57M | - | - | - | - | - | - | - | $221.7K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.1% | - | -67.8% | -46.7% | -63.4% | - | -39.0% | -25.0% | -25.9% | - |
| Return on equity | -8.7% | - | -106.6% | -61.9% | -78.2% | - | -45.6% | -28.9% | -30.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 18.26 | 14.62 | 2.86 | 4.11 | 5.29 | 4.45 | 6.89 | 7.44 | 6.82 | 8.00 |
| Quick ratio | 18.26 | 14.62 | 2.86 | 4.11 | 5.29 | 4.45 | 6.89 | 7.44 | 6.82 | 8.00 |
| Cash ratio | 0.76 | 0.54 | 0.27 | 0.26 | 0.22 | 0.37 | 0.18 | 0.22 | 0.11 | 0.34 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.08 | 1.09 | 1.57 | 1.32 | 1.23 | 1.29 | 1.17 | 1.16 | 1.17 | 1.14 |
| Liabilities / Assets | 0.07 | 0.08 | 0.36 | 0.24 | 0.19 | 0.22 | 0.15 | - | 0.15 | 0.13 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 2.8x | - | 7.0x | 1.2x | 0.4x | - | 2.1x | 1.5x | 1.9x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -6.8% | - | 55.1% | 45.7% | 20.7% | - | -1.4% | 27.7% | 18.3% | - |
| Net income growth (YoY) | -8.5% | - | 53.6% | 44.5% | 19.6% | - | 1.3% | 29.8% | 17.1% | - |
| EPS growth (YoY) | 62.1% | - | 58.3% | 49.2% | 19.4% | - | 45.0% | 29.8% | 18.2% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 874.7% | 143.5% | -80.1% | -74.1% | -68.9% | -58.4% | -52.7% | -44.8% | -42.6% | -39.2% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing RELMADA THERAPEUTICS against the 5 most active filers in the same SIC group.